What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?

Author： Schneeweiss S.   Schoffski O.   Selke G.W.  

Publisher： Elsevier

ISSN： 0168-8510

Source： Health Policy, Vol.44, Iss.3, 1998-06, pp. : 253-260

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The German experience in reference pricing

By Giuliani G.   Selke G.   Garattini L.  

Health Policy, Vol. 44, Iss. 1, 1998-04 ,pp. : 73-85

Elsevier

Access to resources Recommend Favorite

What is Required to Evaluate the Impact of Pharmaceutical Reference Pricing?

By Puig-Junoy Jaume  

Applied Health Economics and Health Policy, Vol. 4, Iss. 2, 2005-01 ,pp. : 87-98

Adis International

Access to resources Recommend Favorite

Review of the literature on reference pricing

By Lopez-Casasnovas G.   Puig-Junoy J.  

Health Policy, Vol. 54, Iss. 2, 2000-11 ,pp. : 87-123

Elsevier

Access to resources Recommend Favorite

Validation of a water consumption questionnaire for a study of the adverse health outcomes associated with disinfection by-products

By Maskiell K.   Heyworth J.   McCaul K.  

International Journal of Environmental Health Research, Vol. 16, Iss. 2, 2006-04 ,pp. : 145-153

Taylor & Francis Ltd

Access to resources Recommend Favorite

Evaluations of health interventions in social insurance-based countries: Germany, the Netherlands, and Austria

By Wild C.   Gibis B.  

Health Policy, Vol. 63, Iss. 2, 2003-02 ,pp. : 187-196

Elsevier

Access to resources Recommend Favorite